Efficacy and Safety of Envafolimab Combined With Capecitabine and Lenvatinib as Postoperative Adjuvant Therapy in Resected Biliary Tract Cancer With High‐Risk Recurrence Factors: A Phase <scp>II</scp> Single‐Center Prospective Study
The adjuvant combination of envafolimab, lenvatinib, and capecitabine demonstrates promising efficacy and a manageable safety profile in high-risk BTC patients after R0 resection. However, these findings still require validation in larger, multicenter, randomized controlled trials.
Authors
- Ruijing Shen
- Yitong Tian (ORCID: https://orcid.org/0009-0005-1650-8065)
- Xuan Zhou (ORCID: https://orcid.org/0000-0003-3919-0342)
- Shijie Li (ORCID: https://orcid.org/0000-0003-4635-5264)
- M. Chen
- Tianao Xie
- Xiujun Cai
- Qingyang Ruan
- Tian Lei
Institutions
- National Instruments (Ireland) (IE)
- Sir Run Run Shaw Hospital (CN)
- Communication University of Zhejiang (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1002/cam4.71756
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00